Knee osteoarthritis
Conditions
Interventions
Control Group:Oral Celecoxib Capsules (Celebrex), 200 mg, once daily
Experimental group:Experimental Group: Oral Celecoxib Capsules (Celebrex) combined with intra-articular injection of Injectable Hyaluronidase 1500 U + 4 ml Normal Saline + 1 ml 2% Lidocaine. 2 ml per
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Diagnosed with knee osteoarthritis (Kellgren-Lawrence [K-L] grade II-III); (2) Recurrent joint swelling, joint pain or pain on movement, and varying degrees of functional limitation; (3) Aged 18 to 80 years; (4) Voluntarily signed the written informed consent form (ICF) and able to comply with the treatment and follow-up procedures.
Exclusion criteria
Exclusion criteria: (1) Diagnosis other than osteoarthritis (including rheumatic arthritis, traumatic arthritis, and infectious arthritis); (2) Allergy to the drugs involved in the trial or occurrence of adverse reactions after previous treatment with hyaluronidase; (3) History of knee surgery (arthroscopic surgery and open surgery); (4) History of knee infection; (5) Patients with active tuberculosis, heart failure, or shock; (6) Patients with malignant tumors; (7) Pregnant women; (8) Mental illness; (9) Cognitive impairment; (10) Neuromuscular dysfunction affecting lower limb function; (11) Complicated with thrombotic events (myocardial infarction, cerebrovascular accident, deep vein thrombosis, or pulmonary embolism); (12) Unable to communicate verbally; (13) Participated in other clinical trials within 30 days prior to the screening visit of this study; (14) Other than the above, reasons judged by the investigator to be unsuitable for participating in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visual Analogue Scale (VAS) score;Osteoarthritis index (WOMAC) pain score;Osteoarthritis index (WOMAC) functional score;Hospital for Special Surgery (HSS) knee score;Effective Rate;Physician Global Assessment(PGA); | — |
Secondary
| Measure | Time frame |
|---|---|
| Imaging examinations (X-ray, MRI, and ultrasound);Incidence of adverse events; | — |
Countries
China
Contacts
Public ContactPengde Kang
West China Hospital, Sichuan University
Outcome results
None listed